We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Exploring Successful Cell and Gene Therapy Development

Successful Cell and Gene Therapy

Cell and gene therapies and regenerative medicines (CGT&RMs) offer remarkable biotherapeutic  promise. However, developing and manufacturing CGT&RMs is no easy task, particularly when choosing how and where to deliver the production of a therapeutic.

There are three primary development options you should consider: building your own infrastructure, local production before shipment or partnering with a contract development and manufacturing organization (CDMO). While owning your infrastructure offers control and proximity to patients, it comes with significant upfront costs and regulatory complexities.

This guide will help you understand the advantages and disadvantages as well as a focus on how to unlock the potential of Japan's thriving CGT&RM market.

Download this guide to discover:

  • Ways foreign CGT&RM manufacturing companies can thrive in Japan
  • Steps to establishing your infrastructure in Japan
  • What to look for in a success-enabling Japan-based CDMO partner

Download Your Guide for FREE Below
Information you provide will be shared with the sponsors for this content. Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.